Increasing system-wide implementation of opioid prescribing guidelines in primary care: findings from a non-randomized stepped-wedge quality improvement project.
Chronic pain
Health care delivery
Opioids
Physician behavior
Primary care
Quality improvement
Journal
BMC family practice
ISSN: 1471-2296
Titre abrégé: BMC Fam Pract
Pays: England
ID NLM: 100967792
Informations de publication
Date de publication:
28 11 2020
28 11 2020
Historique:
received:
12
12
2019
accepted:
15
11
2020
entrez:
29
11
2020
pubmed:
30
11
2020
medline:
25
9
2021
Statut:
epublish
Résumé
Clinician utilization of practice guidelines can reduce inappropriate opioid prescribing and harm in chronic non-cancer pain; yet, implementation of "opioid guidelines" is subpar. We hypothesized that a multi-component quality improvement (QI) augmentation of "routine" system-level implementation efforts would increase clinician adherence to the opioid guideline-driven policy recommendations. Opioid policy was implemented system-wide in 26 primary care clinics. A convenience sample of 9 clinics received the QI augmentation (one-hour academic detailing; 2 online educational modules; 4-6 monthly one-hour practice facilitation sessions) in this non-randomized stepped-wedge QI project. The QI participants were volunteer clinic staff. The target patient population was adults with chronic non-cancer pain treated with long-term opioids. The outcomes included the clinic-level percentage of target patients with a current treatment agreement (primary outcome), rates of opioid-benzodiazepine co-prescribing, urine drug testing, depression and opioid misuse risk screening, and prescription drug monitoring database check; additional measures included daily morphine-equivalent dose (MED), and the percentages of all target patients and patients prescribed ≥90 mg/day MED. T-test, mixed-regression and stepped-wedge-based analyses evaluated the QI impact, with significance and effect size assessed with two-tailed p < 0.05, 95% confidence intervals and/or Cohen's d. Two-hundred-fifteen QI participants, a subset of clinical staff, received at least one QI component; 1255 patients in the QI and 1632 patients in the 17 comparison clinics were prescribed long-term opioids. At baseline, more QI than comparison clinic patients were screened for depression (8.1% vs 1.1%, p = 0.019) and prescribed ≥90 mg/day MED (23.0% vs 15.5%, p = 0.038). The stepped-wedge analysis did not show statistically significant changes in outcomes in the QI clinics, when accounting for the comparison clinics' trends. The Cohen's d values favored the QI clinics in all outcomes except opioid-benzodiazepine co-prescribing. Subgroup analysis showed that patients prescribed ≥90 mg/day MED in the QI compared to comparison clinics improved urine drug screening rates (38.8% vs 19.1%, p = 0.02), but not other outcomes (p ≥ 0.05). Augmenting routine policy implementation with targeted QI intervention, delivered to volunteer clinic staff, did not additionally improve clinic-level, opioid guideline-concordant care metrics. However, the observed effect sizes suggested this approach may be effective, especially in higher-risk patients, if broadly implemented. Not applicable.
Sections du résumé
BACKGROUND
Clinician utilization of practice guidelines can reduce inappropriate opioid prescribing and harm in chronic non-cancer pain; yet, implementation of "opioid guidelines" is subpar. We hypothesized that a multi-component quality improvement (QI) augmentation of "routine" system-level implementation efforts would increase clinician adherence to the opioid guideline-driven policy recommendations.
METHODS
Opioid policy was implemented system-wide in 26 primary care clinics. A convenience sample of 9 clinics received the QI augmentation (one-hour academic detailing; 2 online educational modules; 4-6 monthly one-hour practice facilitation sessions) in this non-randomized stepped-wedge QI project. The QI participants were volunteer clinic staff. The target patient population was adults with chronic non-cancer pain treated with long-term opioids. The outcomes included the clinic-level percentage of target patients with a current treatment agreement (primary outcome), rates of opioid-benzodiazepine co-prescribing, urine drug testing, depression and opioid misuse risk screening, and prescription drug monitoring database check; additional measures included daily morphine-equivalent dose (MED), and the percentages of all target patients and patients prescribed ≥90 mg/day MED. T-test, mixed-regression and stepped-wedge-based analyses evaluated the QI impact, with significance and effect size assessed with two-tailed p < 0.05, 95% confidence intervals and/or Cohen's d.
RESULTS
Two-hundred-fifteen QI participants, a subset of clinical staff, received at least one QI component; 1255 patients in the QI and 1632 patients in the 17 comparison clinics were prescribed long-term opioids. At baseline, more QI than comparison clinic patients were screened for depression (8.1% vs 1.1%, p = 0.019) and prescribed ≥90 mg/day MED (23.0% vs 15.5%, p = 0.038). The stepped-wedge analysis did not show statistically significant changes in outcomes in the QI clinics, when accounting for the comparison clinics' trends. The Cohen's d values favored the QI clinics in all outcomes except opioid-benzodiazepine co-prescribing. Subgroup analysis showed that patients prescribed ≥90 mg/day MED in the QI compared to comparison clinics improved urine drug screening rates (38.8% vs 19.1%, p = 0.02), but not other outcomes (p ≥ 0.05).
CONCLUSIONS
Augmenting routine policy implementation with targeted QI intervention, delivered to volunteer clinic staff, did not additionally improve clinic-level, opioid guideline-concordant care metrics. However, the observed effect sizes suggested this approach may be effective, especially in higher-risk patients, if broadly implemented.
TRIAL REGISTRATION
Not applicable.
Identifiants
pubmed: 33248458
doi: 10.1186/s12875-020-01320-9
pii: 10.1186/s12875-020-01320-9
pmc: PMC7700706
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Subventions
Organisme : Pfizer
ID : 16213567
Pays : International
Références
Jt Comm J Qual Patient Saf. 2015 Oct;41(10):474-9
pubmed: 26404077
Implement Sci. 2018 Jan 25;13(1):21
pubmed: 29370813
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
J Pain. 2006 Sep;7(9):671-81
pubmed: 16942953
Pain Physician. 2012 Jul;15(3 Suppl):S67-116
pubmed: 22786449
Ann Intern Med. 2014 Jan 7;160(1):38-47
pubmed: 24217469
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Pain Med. 2011 Jun;12 Suppl 2:S73-6
pubmed: 21668760
Ann Emerg Med. 2013 Sep;62(3):237-40
pubmed: 23374416
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
Am J Prev Med. 2015 Sep;49(3):409-13
pubmed: 25896191
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Am J Ind Med. 2012 Apr;55(4):325-31
pubmed: 22213274
Pain Physician. 2012 Jul;15(3 Suppl):S1-65
pubmed: 22786448
Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72
pubmed: 14960256
Medicine (Baltimore). 2016 Aug;95(35):e4760
pubmed: 27583928
BMC Health Serv Res. 2018 Jun 5;18(1):415
pubmed: 29871625
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
J Gen Intern Med. 2018 Sep;33(9):1512-1519
pubmed: 29948815
Health Psychol. 2004 Sep;23(5):443-51
pubmed: 15367063